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 The vasculitides are a heterogeneous group of conditions 
typiﬁ ed by their ability to cause vessel inﬂ ammation with or 
without necrosis. They present with a wide variety of signs and 
symptoms and, if left untreated, carry a signiﬁ cant burden of 
mortality and morbidity. The antineutrophil cytoplasmic anti-
body (ANCA)-associated vasculitides (AAV) are three separate 
conditions – granulomatosis with polyangiitis (GPA; formerly 
known as Wegener’s granulomatosis), microscopic polyangi-
itis (MPA), and eosinophilic granulomatosis with polyangiitis 
(EGPA; previously known as Churg-Strauss syndrome). This 
review examines recent developments in the pathogenesis and 
treatment of AAV, focusing on developments in treatment fol-
lowing the introduction of rituximab, in particular.
 
 Introduction 
 The antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitides (AAV) are a collection of relatively 
rare autoimmune diseases of unknown cause, characterised 
by inflammatory cell infiltration causing necrosis of blood 
vessels. The association between ANCA and vasculitis was 
first described in 1982, in a short report describing the 
clinical course of eight patients diagnosed with a segmental 
necrotising glomerulonephritis. 1 The discovery of perinuclear 
and cytoplasmic patterns on indirect immunofluorescence 
(P-ANCA and C-ANCA) and the main specificities 
myeloperoxidase and proteinase 3 (PR3) were recognised in 
the 1980s. The AAV comprise granulomatosis with polyangiitis 
(GPA, previously known as Wegener’s granulomatosis), 
microscopic polyangiitis (MPA) and eosinophilic 
granulomatosis with polyangiitis (EGPA, previously known as 
Churg-Strauss syndrome). 
 Classiﬁcation and epidemiology 
 The American College of Rheumatology in 1990 developed 
classification criteria for GPA and EGPA. Definitions for the 
AAV were described at the Chapel Hill Consensus Conference 
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(CHCC) in 1994 and were revised in 2012 (Table  1 ). 2 The 
Chapel Hill group stress that the CHCC is a nomenclature 
system and not a set of classification or diagnostic criteria. 
The AAV are considered to be small vessel vasculitides but 
there is considerable overlap possible with respect to size 
of vessel involved. The conventional classification based on 
clinical phenotype has been challenged as there is now good 
epidemiological, genetic and clinical evidence to support a 
division based on ANCA subtype. 3 
 GPA, MPA and EGPA have respective annual incidence rates 
of 2.1–14.4, 2.4–10.1 and 0.5–3.7 per million in Europe, and the 
prevalence of AAV is estimated at to be 46–184 per million. 4 
They are more common in those aged over 60 years and slightly 
more common in men. The 5-year survival rates for GPA, MPA 
and EGPA are estimated to be 74–91%, 45–76% and 60–97%, 
respectively. 5 
 Clinical presentation 
 The clinical spectrum of the AAV is broad and hence the 
presentation can be quite varied, ranging from a skin rash 
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to fulminant multisystem disease. Typical features of GPA 
include nasal crusting, stuffiness and epistaxis, uveitis, upper 
respiratory tract involvement and often, when in the context of 
an active urinary sediment, renal involvement. Patients with 
MPA are typically older and present with more severe renal 
disease than GPA together with rash and neuropathy. EGPA 
typically presents with a multisystem disease on a background 
of asthma, nasal polyposis and peripheral blood eosinophilia. 
 Investigation 
 The relative rarity and non-specific presentation of the AAV 
pose diagnostic challenges and often result in a significant 
diagnostic delay of more than 6 months in a third of patients. 
The clue to the diagnosis is often developing multisystem 
involvement; therefore, a very careful and systematic approach 
is required to make the diagnosis. A detailed history and 
examination is required; laboratory investigations should 
include assessments of inflammatory markers, kidney function 
(urea and electrolytes – always with urine dip assessment, 
quantification of urine protein leak and urine microscopy for 
red cell casts), serological testing including ANCA, antinuclear 
antibodies and anti-glomerular basement membrane antibodies 
(both systemic lupus erythematosus and Goodpasture’s 
syndrome can masquerade as AAV). Infection should also be 
excluded and the diagnosis of bacterial endocarditis considered 
and excluded. Chest X-ray should be undertaken. Computerised 
tomography or magnetic resonance imaging may be required to 
assess the chest, brain, orbits and ear, nose and throat structures 
in more detail. A biopsy should always be considered to confirm 
the diagnosis and exclude mimics. However, treatment should 
not necessarily be delayed simply to get a biopsy. Disease 
activity scores such as the Birmingham Vasculitis Activity Score 
(BVAS) can act as a useful aide memoire. 6 BVAS should also 
be recorded to measure disease activity, but training should be 
undertaken so that this tool is used appropriately (available at 
 www.bvasvdi.org ). 
 The role of serial ANCA measurement in determining 
treatment during remission remains controversial. Some 
current evidence suggests patients in whom ANCA remains 
present or rises more than fourfold are at greater risk of relapse. 
It is accepted that more frequent structured clinical assessment 
should be performed rather than a change in therapy based 
solely on ANCA measurement. 7 
 Treatment 
 Remission induction 
 The definition of remission has been standardised by the 
European Vasculitis Society/European League against 
Rheumatism (EUVAS/EULAR) group, who recommend that 
the definition of remission should be one of no detectable 
disease activity using a recognised scoring tool such as BVAS. 8 
 The use of daily cyclophosphamide and glucocorticoids 
improved the dire prognosis of untreated AAV (>80% mortality 
at 1 year) to one of where long-term remission was possible but 
relapses and iatrogenic side effects were common. This changed 
the drive in the research agenda to limit cyclophosphamide 
exposure and, more recently, reduce cumulative glucocorticoid 
dosage. 
 Induction of remission using cyclophosphamide (or 
rituximab) should be considered in all patients with new 
onset AAV. Other induction regimens using methotrexate or 
mycophenolate mofetil should only be considered for patients 
with no evidence of organ or life-threatening disease; this is 
the minority of new patients. In patients presenting with a 
creatinine of >500 µmol/L, the addition of plasma exchange to 
high-dose glucocorticoids and cyclophosphamide or rituximab 
should be considered. An algorithm for the treatment of 
patients with new onset AAV is given in Fig  1 . The majority 
of trials have only included GPA and MPA patients; however, 
EGPA is generally treated using a similar approach. 
 Cyclophosphamide 
 The CYCAZAREM (cyclophosphamide versus azathioprine 
for early remission phase of vasculitis) trial showed that oral 
daily cyclophosphamide (2 mg/kg/day) with glucocorticoids 
 Table 1.  2012 Chapel Hill Consensus Conference definitions for ANCA-associated vasculitis 
Definitions for ANCA-associated vasculitis 
ANCA-associated vasculitis 
(AAV)
Necrotising vasculitis, with few or no immune deposits, predominantly affecting small vessels (ie 
capillaries, venules, arterioles and small arteries), associated with MPO-ANCA or PR3-ANCA. Not all 
patients have ANCA. Add a prefix indicating ANCA reactivity, eg PR3-ANCA, MPO-ANCA, ANCA-negative.
Granulomatosis with 
polyangiitis (Wegener’s) 
Necrotising granulomatous inflammation usually involving the upper and lower respiratory tract, and 
necrotising vasculitis affecting predominantly small to medium vessels (eg capillaries, venules, arterioles, 
arteries and veins). Necrotising glomerulonephritis is common.
Eosinophilic granulomatosis 
with polyangiitis (Churg-
Strauss)
Eosinophil-rich and necrotising granulomatous inflammation often involving the respiratory tract, and 
necrotising vasculitis predominantly affecting small to medium vessels, and associated with asthma and 
eosinophilia. ANCA is more frequent when glomerulonephritis is present.
Microscopic polyangiitis Necrotising vasculitis, with few or no immune deposits, predominantly affecting small vessels (ie 
capillaries, venules or arterioles). Necrotising arteritis involving small and medium arteries may be present. 
Necrotising glomerulonephritis is very common. Pulmonary capillaritis often occurs. Granulomatous 
inflammation is absent.
 ANCA = antineutrophil cytoplasmic antibody; MPO = myeloperoxidase; PR3 = proteinase 3 
 Adapted from Jennette  et al . 2 
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for 3–6 months achieved remission in more than 90% of 
patients. 9 Subsequently, the CYCLOPS trial showed that pulsed 
intravenous cyclophosphamide (10–15 mg/kg) was as effective 
at inducing remission as daily oral cyclophosphamide but with 
a lower cumulative dose of the drug, causing fewer side effects. 
Long-term follow-up of the trial participants revealed an 
increased risk of relapse in those participants who had received 
pulsed cyclophosphamide, but importantly no differences in 
renal function or survival. 10 However, because of the reduced 
total dose of cyclophosphamide associated with pulsed 
regimens, these are favoured in recent guidelines. 11,12 Mesna 
to reduce uroepithelial malignancy and haemorrhagic cystitis 
should be considered for all patients. 
 Rituximab 
 Rituximab in AAV has been tested in two randomised 
controlled trials: RAVE and RITUXVAS. 13,14 In both studies 
participants initially received high-dose glucocorticoids 
with subsequent dose tapering. The rituximab dose in both 
studies was 375 mg/m 2 of body surface area, once a week for 
four infusions. In both trials, rituximab was non-inferior to 
cyclophosphamide and appeared more effective for relapsing 
disease in RAVE. In the RAVE trial, a better response was seen 
in PR3 positive patients. 15 
 An alternative regimen of 1 gm given on two occasions 2 
weeks apart has been widely used and shown to be as effective. 16 
In the UK, rituximab may be used in AAV for primary 
induction in the following circumstances: 
>  for remission induction in newly-diagnosed patients when 
avoiding cyclophosphamide is desirable because of relative 
contraindications, such as previous uroepithelial malignancy, 
premenopausal women who have not completed their 
family, previous cyclophosphamide treatment or inability to 
complete a planned treatment course of cyclophosphamide 
due to allergy or intolerance 
>  when cyclophosphamide has not worked (after 3–6 months 
of treatment), either failure to control active disease or 
disease progression has occurred during the treatment course 
>  for treatment of fi rst relapse 
>  for remission maintenance when rituximab has been used to 
induce remission or when alternative remission maintenance 
agents (azathioprine, methotrexate or mycophenolate 
mofetil) have been ineffective, or have not been tolerated 
because of toxicity. 
 Although the RAVE 13 and RITUXVAS 14 trials only included 
GPA and MPA patients, there is anecdotal evidence from case 
series that rituximab may be effective in EGPA. 
 Remission maintenance 
 After successful remission induction, guidelines recommend 
withdrawing the initial immunosuppressive agent and 
commencing a maintenance regimen with either azathioprine 
or methotrexate. 11,12 However, data are lacking on the precise 
duration of the maintenance regimen and recommendations 
have been made based on expert consensus. Early cessation 
of therapy (<1 year) is associated with an increased risk 
of relapse. 17 It is generally advised that maintenance 
therapy is continued for at least 18–24 months before being 
gradually withdrawn. In general, attempts at reduction of 
glucocorticoids should be made prior to tapering of the 
immunosuppressive remission maintenance agent. The 
risk of relapse is greater in patients who are PR3-ANCA 
 Fig 1.  Algorithm for treating 
ANCA-associated vasculitis. 
AAV = antineutrophil cytoplasmic 
antibody (ANCA)-associated 
vasculitides; AZA = azathioprine; 
CYC = cyclophosphamide; GC = 
glucocorticoids; MMF = mycophe-
nolate mofetil; MTX = methotrex-
ate; PLEX = plasma exchange; 
RTX = rituximab. Reproduced with 
permission from Ntatsaki  et al . 11 
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conditions need to be considered as chronic diseases and 
care needs to be organised into regional networks so that 
all patients benefit from access to appropriate and timely 
advice without necessarily having to travel to a specialist 
centre. ■ 
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positive at presentation and in those who remain PR3-ANCA 
positive when switched from induction to maintenance 
immunosuppression (Table  2 ). 
 The optimum use of rituximab for remission maintenance 
remains to be established. A strategy of fixed interval 
retreatment for up to 2 years appears to be better than 
retreatment based on other clinical relapse, return of 
peripheral B-cells or ANCA status. 18 The MAINRITSAN 
(efficacy study of two treatments in the remission of 
vasculitis) trial reported that rituximab 500 mg given at 
days 0, 14 and at months 6, 12 and 18 was more effective 
in remission maintenance than azathioprine regimen. 19 
Hypogammaglobulinaemia has been observed after rituximab 
treatment and measurement of serum immunoglobulin levels 
prior to each course of rituximab and in those with recurrent 
infection is recommended. 12 
 Treatment intent is now long term and, therefore, attention 
should be paid to the morbidity associated with treatment. 
All patients should be screened for cardiovascular disease 
and appropriate treatment given to reduce risk factors. 
Osteoporosis prevention, immunisation against pneumococcus 
(preferably before immunosuppression is begun) and annual 
influenza vaccination should be given. Patients need specific 
education about their condition and their treatment as they 
may find it difficult to obtain the necessary information. 20 
The increasing complexity of disease management means 
that a multidisciplinary approach is essential for optimal 
management and networks of interested clinicians need to be 
developed. 
 Prognosis 
 Patients with AAV are at risk of complications, both from 
their disease and its treatment. 5 Mortality in the first year is 
mainly due to active vasculitis or infection, late mortality is due 
to infection, cardiovascular disease and malignancy; 5-year 
survival is around 75%. Morbidity accumulates with time 
because of the consequences of active disease and therapies. 
Around one-third of patients have five or more items of damage 
at a mean of 7 years post-diagnosis. 5 
 Conclusions 
 The conditions that comprise AAV are challenging to diagnose 
but improved treatment regimens with the introduction of 
rituximab have improved the outlook for patients. These 
 Table 2.  Factors increasing the risk of relapse 
 Clinical presentation  Serology  Treatment related 
GPA PR3-ANCA at 
presentation
Steroid withdrawal
ENT involvement ANCA positive 
after induction
Immunosuppressive 
withdrawal
Better renal function 
 (creatinine 
<200 μmol/L)
Rise in ANCA 
during treatment
Lower cumulative 
CYC exposure
 ANCA = antineutrophil cytoplasmic antibody; CYC = cyclophosphamide; ENT = 
ear, nose and throat; GPA = granulomatosis with polyangiitis; PR3 = proteinase 3 
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